Complement C3 (C3)

A falling C3 is the question most people arrive with, usually phrased as "my C3 is low, does that mean lupus?" Often it points that way, but the level is describing a process rather than naming a disease. In active systemic lupus erythematosus, the immune system activates complement faster than the liver can replace it, and C3 along with C4 drops. The research correlating disease activity scores with these labs found low C3 in about 92% of patients with active renal involvement and low C4 in about 85%, tying complement consumption tightly to lupus that has reached the kidneys. A falling C3 is read beside lupus-specific antibodies such as the anti-Smith antibody when a clinician is weighing whether disease is active.

That last split is worth slowing down on. The pattern of which protein is low changes the meaning. A low C3 with a low C4 fits the classic lupus picture. A low C3 with a normal C4 points away from it, toward alternative-pathway problems that often involve the kidneys directly. Your doctor reads the two together precisely because the combination, not either value alone, sorts these conditions apart.

Here is the part most consumer pages leave out, and it is the reason a "normal" result can be falsely reassuring. C3 is a positive acute-phase reactant. The liver makes more of it during any generalized inflammation or infection, the same way CRP climbs. So two opposite forces can act on C3 at once during a flare: consumption pulls it down while acute-phase synthesis pushes it back up. In mild-to-moderate inflammation, production can match or outpace the loss, and C3 lands inside the reference range even though disease is active.

This is the answer to "my C3 is normal but I still feel awful." A single in-range value does not rule out a flare. It is one of several reasons rheumatologists never hang a decision on C3 alone, and why a falling trend across several draws often means more than one number that happens to sit at 90.

Put the pieces together and the see-saw resolves into a method clinicians actually use. During active lupus, C3 and C4 usually fall while anti-dsDNA rises. The 2019 EULAR/ACR classification criteria formalize the pairing: low C3 or low C4 alone scores 3 points, low C3 and low C4 together score 4 points, and anti-dsDNA (or anti-Smith) scores 6 points, with a total of 10 or more, plus the entry criterion, classifying SLE. The criteria deliberately weight complement and antibody as separate items, because each adds independent evidence that the two ends of the see-saw are moving in opposite directions.

That framework is meant for classification, not bedside diagnosis, and your own doctor interprets your trend in context. But it explains the ritual of the order set. When a rheumatologist requests C3, C4, and anti-dsDNA on the same draw, they are not collecting three opinions. They are reading one motion from both ends.

Complement C3 belongs to a small group of tests that only make sense together, which is why it is interpreted as part of the broader autoimmune panel rather than as a standalone result. Its closest companions are C4, anti-dsDNA, and the screening ANA that often comes first. If you are trying to make sense of how these results stack up, the walkthrough on reading an autoimmune panel lays out the order in which doctors usually consider them. C3 and C4 are the two complement proteins clinicians watch together in lupus, but they don't always move in step: an isolated low complement C4 with a normal C3 can point toward hereditary angioedema rather than autoimmune activity. In a vasculitis workup, complement levels are read next to antibody patterns such as p-ANCA to gauge how actively the immune process is consuming complement. Falling complement can accompany the broader vasculitis and lupus workup that also tracks antibodies like c-ANCA.

The single most useful habit with C3 is to resist reading one value as a verdict. A number that sits at 90 today means something different if last quarter it was 140 and falling, and something different again if your anti-dsDNA is climbing in step. The see-saw only shows its shape over time.